| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047352667 |
| P356 | DOI | 10.1007/128_2011_232 |
| P932 | PMC publication ID | 3565459 |
| P698 | PubMed publication ID | 21972022 |
| P50 | author | Eddy Arnold | Q29840104 |
| P2093 | author name string | Disha Patel | |
| Joseph D. Bauman | |||
| P2860 | cites work | HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs | Q24646227 |
| Recent developments in fragment-based drug discovery | Q27650535 | ||
| Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design | Q27651402 | ||
| Ultrafast shape recognition to search compound databases for similar molecular shapes. | Q51920977 | ||
| Adding calorimetric data to decision making in lead discovery: a hot tip | Q56452754 | ||
| Fragment-Based Screen against HIV Protease | Q27663595 | ||
| Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor | Q29547710 | ||
| Discovering high-affinity ligands for proteins: SAR by NMR | Q29617569 | ||
| Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA | Q29620616 | ||
| Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium | Q30904604 | ||
| Fragonomics: fragment-based drug discovery | Q33216110 | ||
| SPR-based fragment screening: advantages and applications | Q33304863 | ||
| Integration of fragment screening and library design | Q33308864 | ||
| Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. | Q33786075 | ||
| Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition | Q33896402 | ||
| Fragment screening using X-ray crystallography. | Q33934172 | ||
| A ‘Rule of Three’ for fragment-based lead discovery? | Q33973131 | ||
| Combining biophysical screening and X-ray crystallography for fragment-based drug discovery | Q33991624 | ||
| Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions | Q34092798 | ||
| NMR-based screening in drug discovery | Q34149352 | ||
| Higher throughput calorimetry: opportunities, approaches and challenges | Q34338992 | ||
| Structure-based screening of low-affinity compounds | Q34620191 | ||
| HIV protease inhibitors: peptidomimetic drugs and future perspectives | Q34946303 | ||
| Fragment screening by surface plasmon resonance | Q35181877 | ||
| Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action | Q35185934 | ||
| Tethering: fragment-based drug discovery | Q35771569 | ||
| Fragment-based lead discovery | Q35852295 | ||
| TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization. | Q36186788 | ||
| Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology | Q36651886 | ||
| A decade of fragment-based drug design: strategic advances and lessons learned | Q36732253 | ||
| Fragment-based screening using X-ray crystallography and NMR spectroscopy | Q36938945 | ||
| Fragment-based activity space: smaller is better | Q37100399 | ||
| HIV protease: a novel chemotherapeutic target for AIDS. | Q37254750 | ||
| Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? | Q37604356 | ||
| Structural biology in fragment-based drug design | Q37752790 | ||
| HIV-1 RT-Associated RNase H Function Inhibitors: Recent Advances in Drug Development | Q37790713 | ||
| HIV protease inhibitors: their anti-HIV activity and potential role in treatment | Q40876005 | ||
| Fragment-based lead discovery using X-ray crystallography. | Q45229991 | ||
| Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments | Q45370048 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 181-200 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Topics in Current Chemistry | Q2443282 |
| P1476 | title | Fragment screening and HIV therapeutics | |
| P478 | volume | 317 |
| Q38212854 | "Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets |
| Q27679849 | Crystallographic Fragment-Based Drug Discovery: Use of a Brominated Fragment Library Targeting HIV Protease |
| Q27675974 | Detecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-ray Crystallographic Fragment Screening |
| Q38587368 | Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities |
| Q35181268 | Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery |
| Q35848193 | High-Throughput Screening (HTS) by NMR Guided Identification of Novel Agents Targeting the Protein Docking Domain of YopH. |
| Q36438686 | Rapid experimental SAD phasing and hot-spot identification with halogenated fragments |
| Q36006936 | Structures of endothiapepsin-fragment complexes from crystallographic fragment screening using a novel, diverse and affordable 96-compound fragment library |
Search more.